Barinthus Biotherapeutics (BRNS) Non Operating Income (2020 - 2026)

Barinthus Biotherapeutics has reported Non Operating Income for 7 years, with the latest figure at $525000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 600.0% year-over-year to $525000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.2 million (down 132.74% YoY), and the FY2025 full-year result was $16000.0, down 99.76% from the prior year.
• Non Operating Income for Q1 2026 stood at $525000.0, up from -$3.5 million in the prior quarter.
• The five-year high for Non Operating Income was $6.7 million in Q4 2024, with the low at -$4.4 million in Q4 2023.
• Historically, Non Operating Income has averaged $838437.5 across 5 years, with a median of $474500.0 in 2025.
• Annual changes were most pronounced in 2023 — Non Operating Income tumbled 191.57% — and 2025, when it jumped 1530.77%.
• Barinthus Biotherapeutics' Non Operating Income stood at $4.8 million in 2022, then slumped by 191.57% to -$4.4 million in 2023, then soared by 251.11% to $6.7 million in 2024, then plunged by 152.28% to -$3.5 million in 2025, then surged by 115.0% to $525000.0 in 2026.
• The last three Non Operating Income figures came in at $525000.0 (Q1 2026), -$3.5 million (Q4 2025), and $424000.0 (Q3 2025), per Business Quant data.